We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Lilly, BI Get Tentative FDA Approval for Insulin Basaglar as an NDA
Lilly, BI Get Tentative FDA Approval for Insulin Basaglar as an NDA
Eli Lilly and Boehringer Ingelheim have won tentative FDA approval for their insulin product Basaglar, which is considered the biosimilar of a Sanofi product in Europe but is being reviewed as its own NDA in the United States.